Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

166.90 -7.10 (-4.08%)

Delayed Quote Updated: 2:55 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Top US Stock Gainers and Losers for Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

Alnylam (ALNY) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

AMVUTTRA revenue jumped 65% year over year as TTR franchise momentum accelerates.

Via The Motley Fool

Topics Earnings

Alnylam Pharmaceuticals Q3 Earnings Call Highlights ↗

October 29, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its...

Via MarketBeat

Topics Earnings

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum ↗

October 16, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth ↗

October 08, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗

September 03, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention ↗

August 20, 2026

Via Chartmill

Premarket Gainers and Losers on Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

October 29, 2026

From Alnylam Pharmaceuticals

Via Business Wire

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial ↗

October 26, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington’s disease, reporting dose-dependent reductions in...

Via MarketBeat

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

October 23, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

This beaten-down biotech has a better story than its stock chart suggests.

Via The Motley Fool

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

October 15, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Via The Motley Fool

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and...

Via MarketBeat

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗

September 19, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with...

Via MarketBeat

Topics Death

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Analysts think Alnylam could rebound strongly over the next 12 months.

Via The Motley Fool

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

September 11, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 15.67%. Currently, Alnylam Pharmaceuticals...

Via Benzinga

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

September 02, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 28, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on an annualized basis producing an average annual return of 15.09%. Currently, Alnylam Pharmaceuticals...

Via Benzinga

Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP

August 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

August 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP

August 20, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 19, 2026

From Kirby McInerney LLP

Via Business Wire

NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc.

August 19, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm

August 18, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.